Briggs Morrison - Feb 2, 2023 Form 4 Insider Report for Syndax Pharmaceuticals Inc (SNDX)

Role
President, Head of R&D, Director
Signature
/s/ Michael A. Metzger, Attorney-in-fact
Stock symbol
SNDX
Transactions as of
Feb 2, 2023
Transactions value $
$913,600
Form type
4
Date filed
2/3/2023, 04:02 PM
Previous filing
Sep 21, 2022
Next filing
Feb 8, 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SNDX Stock Options (Right to buy) Award $914K +32K $28.55 32K Feb 2, 2023 Common Stock 32K $28.55 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 1/48th of the shares subject to the option shall vest monthly over a four-year period.